Cargando…

The Diagnostic and Differential Diagnosis Utility of Cerebrospinal Fluid α-Synuclein Levels in Parkinson's Disease: A Meta-Analysis

Several recent studies showed that α-syn might be a potential diagnostic biomarker for PD in human cerebrospinal fluid (CSF), but the results were inconsistent. The purpose of this meta-analysis was to investigate the diagnostic and differential diagnosis efficacy of CSF α-syn in PD. Studies which m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Bo, Wen, Min, Yu, Wen-Feng, Zhang, Chun-Lin, Jiao, Ling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532865/ https://www.ncbi.nlm.nih.gov/pubmed/26336612 http://dx.doi.org/10.1155/2015/567386

Ejemplares similares

Comparative study of cerebrospinal fluid α‐synuclein seeding aggregation assays for diagnosis of Parkinson's disease
por: Kang, Un Jung, et al.
Publicado: (2019)

Longitudinal Analyses of Cerebrospinal Fluid α-Synuclein in Prodromal and Early Parkinson’s Disease
por: Mollenhauer, Brit, et al.
Publicado: (2019)

A meta-analysis of the diagnostic utility of biomarkers in cerebrospinal fluid in Parkinson’s disease
por: Xiang, Chunchen, et al.
Publicado: (2022)

Cerebrospinal Fluid Lysosomal Enzymes and Alpha-Synuclein in Parkinson's Disease
por: Parnetti, Lucilla, et al.
Publicado: (2014)

Elevated Levels of α-Synuclein Oligomer in the Cerebrospinal Fluid of Drug-Naïve Patients with Parkinson's Disease
por: Park, Min Jeong, et al.
Publicado: (2011)

α‐synuclein RT‐QuIC in cerebrospinal fluid of LRRK2‐linked Parkinson's disease
por: Garrido, Alicia, et al.
Publicado: (2019)

α‐Synuclein real‐time quaking‐induced conversion in the cerebrospinal fluid of uncertain cases of parkinsonism
por: van Rumund, Anouke, et al.
Publicado: (2019)

Baseline Cerebrospinal Fluid α-Synuclein in Parkinson’s Disease Is Associated with Disease Progression and Cognitive Decline
por: Emdina, Anna, et al.
Publicado: (2022)

Cerebrospinal Fluid α-Synuclein Species in Cognitive and Movements Disorders
por: Constantinides, Vasilios C., et al.
Publicado: (2021)

Mini Review: Correlations of Cognitive Domains With Cerebrospinal Fluid α-Synuclein Levels in Patients With Parkinson's Disease
por: Murakami, Hidetomo, et al.
Publicado: (2021)

Author Correction: A meta-analysis of the diagnostic utility of biomarkers in cerebrospinal fluid in Parkinson’s disease
por: Xiang, Chunchen, et al.
Publicado: (2023)

Interlaboratory validation of cerebrospinal fluid α-synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease
por: Kruse, Niels, et al.
Publicado: (2018)

α‐Synuclein Seed Amplification Assays in the Diagnosis of Synucleinopathies Using Cerebrospinal Fluid—A Systematic Review and Meta‐Analysis
por: Grossauer, Anna, et al.
Publicado: (2023)

AlphaLISA detection of alpha-synuclein in the cerebrospinal fluid and its potential application in Parkinson’s disease diagnosis
por: Zhao, Hongli, et al.
Publicado: (2017)

α-synuclein−lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson's disease patients
por: Paslawski, Wojciech, et al.
Publicado: (2019)

Baseline concentration of misfolded α‐synuclein aggregates in cerebrospinal fluid predicts risk of cognitive decline in Parkinson's disease
por: Ning, H., et al.
Publicado: (2018)

Ultrasonication-based rapid amplification of α-synuclein aggregates in cerebrospinal fluid
por: Kakuda, Keita, et al.
Publicado: (2019)

Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies
por: Poggiolini, Ilaria, et al.
Publicado: (2021)

Does TRODAT-1 SPECT Uptake Correlate with Cerebrospinal Fluid α-Synuclein Levels in Mid-Stage Parkinson’s Disease?
por: Coutinho, Artur M., et al.
Publicado: (2023)

Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis
por: Eusebi, Paolo, et al.
Publicado: (2016)

Detection of disease-associated α-synuclein in the cerebrospinal fluid: a feasibility study
por: Unterberger, Ursula, et al.
Publicado: (2014)

The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer’s disease
por: Twohig, Daniel, et al.
Publicado: (2018)

α‐Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2018)

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2014)

Single‐Molecule Counting Coupled to Rapid Amplification Enables Detection of α‐Synuclein Aggregates in Cerebrospinal Fluid of Parkinson's Disease Patients
por: Bhumkar, Akshay, et al.
Publicado: (2021)

Cerebrospinal fluid α-synuclein predicts neurodegeneration and clinical progression in non-demented elders
por: Li, Jie-Qiong, et al.
Publicado: (2020)

Cerebrospinal fluid α synuclein concentrations in patients with positive AD biomarkers and extrapyramidal symptoms
por: Winkel, Izabela, et al.
Publicado: (2021)

Clearing Extracellular Alpha-Synuclein from Cerebrospinal Fluid: A New Therapeutic Strategy in Parkinson’s Disease
por: Menéndez-González, Manuel, et al.
Publicado: (2018)

α-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system
por: Mollenhauer, Brit, et al.
Publicado: (2012)

α‐Synuclein RT‐QuIC assay in cerebrospinal fluid of patients with dementia with Lewy bodies
por: Bongianni, Matilde, et al.
Publicado: (2019)

High diagnostic performance of plasma and cerebrospinal fluid beta‐synuclein for sporadic Creutzfeldt–Jakob disease
por: Abu‐Rumeileh, Samir, et al.
Publicado: (2023)

Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels
por: Ibanez, Laura, et al.
Publicado: (2017)

Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies
por: Foulds, P.G., et al.
Publicado: (2012)

α-Synuclein and DJ-1 as Potential Biological Fluid Biomarkers for Parkinson’s Disease
por: Waragai, Masaaki, et al.
Publicado: (2010)

Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers
por: Aasly, Jan O., et al.
Publicado: (2014)

Cerebrospinal fluid lipoproteins inhibit α-synuclein aggregation by interacting with oligomeric species in seed amplification assays
por: Bellomo, Giovanni, et al.
Publicado: (2023)

Assessment of Aggregated and Exosome-Associated α-Synuclein in Brain Tissue and Cerebrospinal Fluid Using Specific Immunoassays
por: Anagnostou, Dimitrios, et al.
Publicado: (2023)

Evaluation of α-synuclein and apolipoprotein E as potential biomarkers in cerebrospinal fluid to monitor pharmacotherapeutic efficacy in dopamine dictated disease states of Parkinson’s disease and schizophrenia
por: Gupta, Ashish Kumar, et al.
Publicado: (2019)

A Meta-Analysis of α-Synuclein Multiplication in Familial Parkinsonism
por: Book, Adam, et al.
Publicado: (2018)

Differential Diagnosis of Multiple System Atrophy-Parkinsonism and Parkinson's Disease Using α-Synuclein and External Anal Sphincter Electromyography
por: Cao, Zhentang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lac0tcftf2m09t97m91ckq4g5g